Yujia Liang, Shufang Ning, Mekhrdod S Kurboniyon, Khaiyom Rahmonov, Zhengmin Cai, Shirong Li, Jinling Mai, Xiaojing He, Lijuan Liu, Liping Tang, Litu Zhang, Chen Wang
{"title":"PdRu bimetallic nanoalloys with improved photothermal effect for amplified ROS-mediated tumor therapy.","authors":"Yujia Liang, Shufang Ning, Mekhrdod S Kurboniyon, Khaiyom Rahmonov, Zhengmin Cai, Shirong Li, Jinling Mai, Xiaojing He, Lijuan Liu, Liping Tang, Litu Zhang, Chen Wang","doi":"10.3389/fbioe.2024.1523599","DOIUrl":null,"url":null,"abstract":"<p><p>An emerging strategy in cancer therapy involves inducing reactive oxygen species (ROS), specifically within tumors using nanozymes. However, existing nanozymes suffer from limitations such as low reactivity, poor biocompatibility, and limited targeting capabilities, hindering their therapeutic efficacy. In response, the PdRu@PEI bimetallic nanoalloys were constructed with well-catalytic activities and effective separation of charges, which can catalyze hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to toxic hydroxyl radical (·OH) under near-infrared laser stimulation. Through facilitating electron transfer and enhancing active sites, the enhanced peroxidase-like (POD-like) enzymatic activity and glutathione (GSH) depletion abilities of nanozymes are boosted through a simple co-reduction process, leading to promising anti-tumor activity. The electron transfer between Pd and Ru of PdRu@PEI nanoalloys contributes to POD-like activity. Then, by oxidizing endogenous overexpressed GSH, enzymatic cycling prevents GSH from consuming ROS. Furthermore, the surface plasmon resonance effect of near-infrared laser on bimetallic nanoalloys ensures its photothermal performance and its local heating, further promoting POD-like activity. The integrated multi-modal therapeutic approach of PdRu@PEI has demonstrated significant anti-cancer effects <i>in vivo</i> studies. The nanozymes exhibit high catalytic efficiency and excellent biocompatibility, offering valuable insights for the development of nano-catalysts/enzymes for biomedical applications.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"12 ","pages":"1523599"},"PeriodicalIF":4.3000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739111/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2024.1523599","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
An emerging strategy in cancer therapy involves inducing reactive oxygen species (ROS), specifically within tumors using nanozymes. However, existing nanozymes suffer from limitations such as low reactivity, poor biocompatibility, and limited targeting capabilities, hindering their therapeutic efficacy. In response, the PdRu@PEI bimetallic nanoalloys were constructed with well-catalytic activities and effective separation of charges, which can catalyze hydrogen peroxide (H2O2) to toxic hydroxyl radical (·OH) under near-infrared laser stimulation. Through facilitating electron transfer and enhancing active sites, the enhanced peroxidase-like (POD-like) enzymatic activity and glutathione (GSH) depletion abilities of nanozymes are boosted through a simple co-reduction process, leading to promising anti-tumor activity. The electron transfer between Pd and Ru of PdRu@PEI nanoalloys contributes to POD-like activity. Then, by oxidizing endogenous overexpressed GSH, enzymatic cycling prevents GSH from consuming ROS. Furthermore, the surface plasmon resonance effect of near-infrared laser on bimetallic nanoalloys ensures its photothermal performance and its local heating, further promoting POD-like activity. The integrated multi-modal therapeutic approach of PdRu@PEI has demonstrated significant anti-cancer effects in vivo studies. The nanozymes exhibit high catalytic efficiency and excellent biocompatibility, offering valuable insights for the development of nano-catalysts/enzymes for biomedical applications.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.